CL2014002283A1 - Forma de dosificacion oral solida de liberacion inmediata que comprende particulas que comprenden un nucleo con un primer agente activo, un recubrimiento con un segundo agente activo sobre el y un material sensible al ph acido sobre dicho nucleo recubierto; proceso para prepararla; metodo de tratamiento; y uso para tratar dolor. - Google Patents

Forma de dosificacion oral solida de liberacion inmediata que comprende particulas que comprenden un nucleo con un primer agente activo, un recubrimiento con un segundo agente activo sobre el y un material sensible al ph acido sobre dicho nucleo recubierto; proceso para prepararla; metodo de tratamiento; y uso para tratar dolor.

Info

Publication number
CL2014002283A1
CL2014002283A1 CL2014002283A CL2014002283A CL2014002283A1 CL 2014002283 A1 CL2014002283 A1 CL 2014002283A1 CL 2014002283 A CL2014002283 A CL 2014002283A CL 2014002283 A CL2014002283 A CL 2014002283A CL 2014002283 A1 CL2014002283 A1 CL 2014002283A1
Authority
CL
Chile
Prior art keywords
active agent
core
prepare
particles
coating
Prior art date
Application number
CL2014002283A
Other languages
English (en)
Spanish (es)
Inventor
Akwete L Adjei
Sibao Chen
Robert Joe Kupper
Vincent Mancinelli
Original Assignee
Rhodes Pharmaceuticals Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48044945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002283(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhodes Pharmaceuticals Lp filed Critical Rhodes Pharmaceuticals Lp
Publication of CL2014002283A1 publication Critical patent/CL2014002283A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014002283A 2012-03-02 2014-08-28 Forma de dosificacion oral solida de liberacion inmediata que comprende particulas que comprenden un nucleo con un primer agente activo, un recubrimiento con un segundo agente activo sobre el y un material sensible al ph acido sobre dicho nucleo recubierto; proceso para prepararla; metodo de tratamiento; y uso para tratar dolor. CL2014002283A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606156P 2012-03-02 2012-03-02
US201261724141P 2012-11-08 2012-11-08

Publications (1)

Publication Number Publication Date
CL2014002283A1 true CL2014002283A1 (es) 2015-04-17

Family

ID=48044945

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002283A CL2014002283A1 (es) 2012-03-02 2014-08-28 Forma de dosificacion oral solida de liberacion inmediata que comprende particulas que comprenden un nucleo con un primer agente activo, un recubrimiento con un segundo agente activo sobre el y un material sensible al ph acido sobre dicho nucleo recubierto; proceso para prepararla; metodo de tratamiento; y uso para tratar dolor.

Country Status (21)

Country Link
US (3) US11173155B2 (OSRAM)
EP (2) EP3170492B1 (OSRAM)
JP (2) JP6199321B2 (OSRAM)
CN (2) CN104144681A (OSRAM)
AR (1) AR090218A1 (OSRAM)
AU (2) AU2013203493B2 (OSRAM)
CA (1) CA2852042C (OSRAM)
CL (1) CL2014002283A1 (OSRAM)
EA (1) EA028224B1 (OSRAM)
ES (2) ES2619574T3 (OSRAM)
IL (1) IL234256B (OSRAM)
IN (1) IN2014MN01901A (OSRAM)
MX (1) MX354677B (OSRAM)
NZ (1) NZ629468A (OSRAM)
PE (1) PE20142320A1 (OSRAM)
PH (1) PH12014501910A1 (OSRAM)
SG (1) SG11201405011PA (OSRAM)
TW (2) TW201722406A (OSRAM)
UY (1) UY34651A (OSRAM)
WO (1) WO2013128276A2 (OSRAM)
ZA (1) ZA201405960B (OSRAM)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
PL2124556T3 (pl) 2006-10-09 2015-02-27 Charleston Laboratories Inc Kompozycje farmaceutyczne
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
PL2997965T3 (pl) 2009-07-22 2019-06-28 Grünenthal GmbH Odporna na manipulacje postać dawkowania opioidów wrażliwych na utlenianie
ES2487244T3 (es) 2010-09-02 2014-08-20 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende un polímero aniónico
EP2611426B1 (en) 2010-09-02 2014-06-25 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
HRP20181716T1 (hr) 2012-04-18 2018-12-28 Grünenthal GmbH Farmaceutski oblik doziranja otporan na zlonamjernu uporabu i naglo oslobađanje cjelokupne doze
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
WO2015004245A1 (en) 2013-07-12 2015-01-15 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
EP3062778A4 (en) * 2013-10-31 2017-07-19 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
WO2015065547A1 (en) * 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015120201A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma, Llc Abuse-resistant drug formulations with built-in overdose protection
JP6510628B2 (ja) * 2014-03-26 2019-05-15 サン・ファーマ・アドバンスト・リサーチ・カンパニー・リミテッド 乱用防止即時放出性被覆リザーバ固体剤形
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2016094358A1 (en) * 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
JP2018513872A (ja) * 2015-04-24 2018-05-31 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 異なる粒子から２種の薬物の急速放出をもたらすタンパレジスタントな固定用量組合せ
WO2016170094A1 (en) * 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles
AU2016251852A1 (en) * 2015-04-24 2017-11-09 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a powder
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
WO2016170093A1 (en) * 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix
US20180185352A1 (en) * 2015-06-09 2018-07-05 KVK-Tech, Inc. Abuse deterrent pharmaceutical compositions
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US11564918B2 (en) 2016-10-10 2023-01-31 Rhodes Pharmaceuticals L.P. Pharmaceutical resinate compositions and methods of making and using thereof
WO2018119108A1 (en) * 2016-12-21 2018-06-28 Tioga Pharmaceuticals Inc. Splid pharmaceutical formulations of asimadoline
WO2019074829A1 (en) 2017-10-09 2019-04-18 Rhodes Pharmaceuticals L.P. RESINATE-BASED PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEM
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN117715538A (zh) * 2021-05-03 2024-03-15 剑桥糖质科学有限公司 可溶性糖和不溶性糖的组合物及相关方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6740341B1 (en) 1998-11-25 2004-05-25 Cima Labs Inc. Taste masking rapid release coating system
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
BR0212020A (pt) * 2001-08-06 2005-08-16 Euro Celtique Sa Formas de dosagem, métodos para impedir o abuso de uma forma de dosagem, métodos para impedir o desvio de uma forma de dosagem, métodos para o tratamento de dor e método de preparação de uma forma de dosagem
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US6455557B1 (en) 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US20040091544A1 (en) * 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
US20040228830A1 (en) * 2003-01-28 2004-11-18 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
FR2850576B1 (fr) 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
CN1897924B (zh) * 2003-09-26 2011-09-21 阿尔扎公司 能提供高载药量的药物包衣和提供它的方法
EP2210605B1 (en) * 2003-11-04 2017-03-01 TCD Royalty Sub, LLC Once daily dosage forms of trospium
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI483944B (zh) 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US8193211B2 (en) * 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
CA2608361A1 (en) * 2005-05-13 2006-11-23 Alpharma, Inc. Morphine sulphate formulations
SG184754A1 (en) 2005-12-28 2012-10-30 Takeda Pharmaceutical Controlled release solid preparation
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
WO2007120135A1 (en) * 2006-04-17 2007-10-25 Forest Laboratories, Inc. Lercanidipine immediate release composition
CL2007001194A1 (es) * 2006-04-27 2008-01-04 Takeda Pharmaceutical Preparacion farmaceutica solida que comprende particulas que comprenden (i) particulas de nucleo con excipiente y (ii) pioglitazona o una sal de la misma y un polimero soluble en acido, como copolimero de aminoalquil metacrilato e o dietilaminoacetato de polivinilacetal, ambos recubriendo el nucleo
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
FR2904225B1 (fr) * 2006-07-28 2010-08-13 Bouchara Recordati Compositions pharmaceutiques de substances actives difficilement detournables de la voie d'administration a laquelle elles sont destinees
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
JP4707073B2 (ja) * 2008-09-30 2011-06-22 アステラス製薬株式会社 アトルバスタチン経口投与用粒子状医薬組成物
WO2010044842A1 (en) 2008-10-16 2010-04-22 University Of Tennessee Research Foundation Tamper resistant oral dosage forms containing an embolizing agent
US8460640B2 (en) * 2008-12-12 2013-06-11 Paladin Labs, Inc. Narcotic drug formulations with decreased abuse potential
JP5667575B2 (ja) * 2008-12-16 2015-02-12 パラディン ラブス インコーポレーテッド 誤用を防止する放出制御製剤
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
BR112012010102B8 (pt) * 2009-10-28 2021-05-25 Basf Se material de revestimento, uso de materiais de revestimento, e, revestimentos de película para formas de dosagem farmacêuticas
ES2780182T3 (es) 2011-06-29 2020-08-24 Allergan Inc Formulaciones de 15-hidroxiestearato de macrogol
EP2755640B1 (en) * 2011-09-16 2017-07-26 Purdue Pharma LP Tamper resistant pharmaceutical formulations

Also Published As

Publication number Publication date
AU2013203493A1 (en) 2013-09-19
EA028224B1 (ru) 2017-10-31
MX354677B (es) 2018-03-15
AR090218A1 (es) 2014-10-29
ZA201405960B (en) 2016-03-30
JP2015511953A (ja) 2015-04-23
EP3170492B1 (en) 2020-07-08
JP6199321B2 (ja) 2017-09-20
JP6509287B2 (ja) 2019-05-08
PE20142320A1 (es) 2015-01-16
ES2821773T3 (es) 2021-04-27
EP2819653A2 (en) 2015-01-07
WO2013128276A2 (en) 2013-09-06
NZ629468A (en) 2017-08-25
CA2852042A1 (en) 2013-09-06
UY34651A (es) 2013-09-30
ES2619574T3 (es) 2017-06-26
CN104144681A (zh) 2014-11-12
WO2013128276A3 (en) 2013-12-27
CN109820830A (zh) 2019-05-31
EP3170492A1 (en) 2017-05-24
US20220031693A1 (en) 2022-02-03
US20150030677A1 (en) 2015-01-29
AU2016202846A1 (en) 2016-05-26
AU2013203493B2 (en) 2016-02-04
CA2852042C (en) 2018-05-01
SG11201405011PA (en) 2014-09-26
TWI614037B (zh) 2018-02-11
JP2018012711A (ja) 2018-01-25
PH12014501910B1 (en) 2014-11-24
US20240423974A1 (en) 2024-12-26
IL234256B (en) 2020-08-31
IN2014MN01901A (OSRAM) 2015-07-10
PH12014501910A1 (en) 2014-11-24
AU2016202846B2 (en) 2017-06-01
TW201350142A (zh) 2013-12-16
US11173155B2 (en) 2021-11-16
EP2819653B1 (en) 2017-01-11
MX2014010534A (es) 2015-05-11
US12128042B2 (en) 2024-10-29
EA201400972A1 (ru) 2015-02-27
TW201722406A (zh) 2017-07-01

Similar Documents

Publication Publication Date Title
CL2014002283A1 (es) Forma de dosificacion oral solida de liberacion inmediata que comprende particulas que comprenden un nucleo con un primer agente activo, un recubrimiento con un segundo agente activo sobre el y un material sensible al ph acido sobre dicho nucleo recubierto; proceso para prepararla; metodo de tratamiento; y uso para tratar dolor.
CL2014001070A1 (es) Compuestos derivados de aminoácidos funcionalizados en el n-terminal, capaces de formar micro- o nanopartículas para encapsular un agente; composición; uso para tratar enfermedades; y método de suministro de un polinucleótido a una célula.
CL2013001120A1 (es) Una dispersion solida que comprende un agente inductor de apoptosis de formula definida dispersado en una matriz solida que comprende a) al menos un vehiculo polimerico soluble en agua y b) al menos un surfactante; proceso de preparacion; forma de dosificacion oral, util para tratar una enfermedad neoplasica, inmune o autoinmune.
CL2014001172A1 (es) Un portador para la liberacion controlada de agentes activos que comprende un nucleo de cabonato de calcio y un agente activo, y un recubrimiento que encapsula al nucleo; metodo para preparar el portador, y su uso en controlar la liberacion de un agente activo
BR112015002541A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
BR112013023175A2 (pt) composto, inibidor, medicamento, agente anticâncer, composição farmacêutica, método para o tratamento de câncer, e, uso de um composto
BR112014028723A2 (pt) forma cristalina, seu processo de produção e mistura, agente de proteção, uso da forma cristalina e método para o combate
LT3216448T (lt) Paraziticidinės peroralinės veterinarinės kompozicijos, apimančios sisteminio poveikio veikliuosius agentus, būdai ir jų panaudojimas
CL2012002909A1 (es) Procedimiento de preparación de una composición farmacéutica que comprenden a) un centro granulado constituido por granos de principio activo aglomerados en presencia de aglomerante y b) una capa de recubrimiento de dicho centro granulado constituido por matriz grasa; composición farmacéutica; y su uso para administración oral
PL2908798T3 (pl) Pasek do wprowadzania środka aktywującego higienę jamy ustnej i sposoby stosowania środków aktywujących higienę jamy ustnej
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BR112014009634A2 (pt) preparação e agente terapêutico
CL2014002795A1 (es) Una formulacion de farmaco de liberacion retardada oral para suministrar un farmaco al colon que comprende un nucleo y un recubrimiento para el nucleo, el nucleo comprende un farmaco y el recubrimiento comprende una capa exterior con una mezcla de un primer y segundo material polimerico y una capa interior con un tercer material polimerico; y su metodo de preparacion.
BR112012015540A2 (pt) composto, uso de composto, método para tratar um individuo, método de inibir janus quinases em um individuo, composição farmacêutica e combinação de produto
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CL2013002033A1 (es) Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar.
BR112013014169A2 (pt) composição para uso em cápsulas de moldagem por revestimento externo e método de formação da composição
BR112013018953A2 (pt) composição efervescente na forma sólida para uso em aplicações vaginais para o tratamento de infecções vaginais.
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
CL2013002504A1 (es) Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
AR083208A1 (es) Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion
CL2014000844A1 (es) Formulacion farmaceutica oral de liberacion prolongada en forma de multiparticulas, que comprende a) 40-o-(2-hidroxi)etil-rapamicina y b) al menos un recubrimiento de liberacion prolongada.
ZA201508454B (en) Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component
BR112013004829A2 (pt) composição de agente de dispersão de produto químico agrícola, composição química agrícola, método para produzir um produto agrícola, método para aumentar eficácia em um produto químico agrícola, e uso da composição de agente de dispersão de produto químico agrícola.